147 related articles for article (PubMed ID: 11570906)
1. Immunohistochemical analysis of nuclear versus cytoplasmic staining of WT1 in malignant mesotheliomas and primary pulmonary adenocarcinomas.
Foster MR; Johnson JE; Olson SJ; Allred DC
Arch Pathol Lab Med; 2001 Oct; 125(10):1316-20. PubMed ID: 11570906
[TBL] [Abstract][Full Text] [Related]
2. Cytologic malignancy versus benignancy: how useful are the "newer" markers in body fluid cytology?
Lyons-Boudreaux V; Mody DR; Zhai J; Coffey D
Arch Pathol Lab Med; 2008 Jan; 132(1):23-8. PubMed ID: 18181669
[TBL] [Abstract][Full Text] [Related]
3. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 2003 Aug; 27(8):1031-51. PubMed ID: 12883236
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies.
Abutaily AS; Addis BJ; Roche WR
J Clin Pathol; 2002 Sep; 55(9):662-8. PubMed ID: 12194995
[TBL] [Abstract][Full Text] [Related]
5. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma.
Oates J; Edwards C
Histopathology; 2000 Apr; 36(4):341-7. PubMed ID: 10759948
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma.
Kushitani K; Takeshima Y; Amatya VJ; Furonaka O; Sakatani A; Inai K
Pathol Int; 2007 Apr; 57(4):190-9. PubMed ID: 17316414
[TBL] [Abstract][Full Text] [Related]
7. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
[TBL] [Abstract][Full Text] [Related]
8. Calretinin and other mesothelioma markers in synovial sarcoma: analysis of antigenic similarities and differences with malignant mesothelioma.
Miettinen M; Limon J; Niezabitowski A; Lasota J
Am J Surg Pathol; 2001 May; 25(5):610-7. PubMed ID: 11342772
[TBL] [Abstract][Full Text] [Related]
9. Mesothelioma with signet-ring cell features: report of 23 cases.
Ordóñez NG
Mod Pathol; 2013 Mar; 26(3):370-84. PubMed ID: 23041828
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: a comparative study.
Ordóñez NG; Sahin AA
Hum Pathol; 2014 Jul; 45(7):1529-40. PubMed ID: 24816068
[TBL] [Abstract][Full Text] [Related]
11. Distinctive microvillous brush border staining with HBME-1 distinguishes pleural mesotheliomas from pulmonary adenocarcinomas.
Dahlstrom JE; Maxwell LE; Brodie N; Zardawi IM; Jain S
Pathology; 2001 Aug; 33(3):287-91. PubMed ID: 11523926
[TBL] [Abstract][Full Text] [Related]
12. Malignant mesotheliomas. Improved differential diagnosis from lung adenocarcinomas using monoclonal antibodies 44-3A6 and 624A12.
Lee I; Radosevich JA; Chejfec G; Ma YX; Warren WH; Rosen ST; Gould VE
Am J Pathol; 1986 Jun; 123(3):497-507. PubMed ID: 3717302
[TBL] [Abstract][Full Text] [Related]
13. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 2000 Apr; 24(4):598-606. PubMed ID: 10757409
[TBL] [Abstract][Full Text] [Related]
14. The immunohistochemical profile of malignant mesotheliomas of the tunica vaginalis: a study of 20 cases.
Winstanley AM; Landon G; Berney D; Minhas S; Fisher C; Parkinson MC
Am J Surg Pathol; 2006 Jan; 30(1):1-6. PubMed ID: 16330935
[TBL] [Abstract][Full Text] [Related]
15. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma.
Ordóñez NG
Mod Pathol; 1998 Oct; 11(10):929-33. PubMed ID: 9796717
[TBL] [Abstract][Full Text] [Related]
16. Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study.
Lucas DR; Pass HI; Madan SK; Adsay NV; Wali A; Tabaczka P; Lonardo F
Histopathology; 2003 Mar; 42(3):270-9. PubMed ID: 12605647
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis.
Carella R; Deleonardi G; D'Errico A; Salerno A; Egarter-Vigl E; Seebacher C; Donazzan G; Grigioni WF
Am J Surg Pathol; 2001 Jan; 25(1):43-50. PubMed ID: 11145250
[TBL] [Abstract][Full Text] [Related]
18. CD10 and calretinin staining of endocervical glandular lesions, endocervical stroma and endometrioid adenocarcinomas of the uterine corpus: CD10 positivity is characteristic of, but not specific for, mesonephric lesions and is not specific for endometrial stroma.
McCluggage WG; Oliva E; Herrington CS; McBride H; Young RH
Histopathology; 2003 Aug; 43(2):144-50. PubMed ID: 12877729
[TBL] [Abstract][Full Text] [Related]
19. Podoplanin is a better immunohistochemical marker for sarcomatoid mesothelioma than calretinin.
Padgett DM; Cathro HP; Wick MR; Mills SE
Am J Surg Pathol; 2008 Jan; 32(1):123-7. PubMed ID: 18162779
[TBL] [Abstract][Full Text] [Related]
20. [Value of immunocytochemistry in differential diagnosis of gastric adenocarcinoma, reactive mesothelial cells and malignant epithelial mesothelioma in metastatic effusion fluid].
Lyu M; Cha N; Zou YF; Leng JH; Xu L; Sun Y; Hao YY
Zhonghua Bing Li Xue Za Zhi; 2018 Mar; 47(3):180-185. PubMed ID: 29534357
[No Abstract] [Full Text] [Related]
[Next] [New Search]
